CRVS — Corvus Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $625.09m
- $559.40m
- 37
- 18
- 91
- 46
Annual income statement for Corvus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.3 | 38.6 | 32.6 | 23.4 | 27.5 |
| Operating Profit | -6.3 | -38.6 | -32.6 | -23.4 | -27.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6 | -43.2 | -41.3 | -27 | -62.3 |
| Net Income After Taxes | -6 | -43.2 | -41.3 | -27 | -62.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6 | -43.2 | -41.3 | -27 | -62.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6 | -43.2 | -41.3 | -27 | -62.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.47 | -1.03 | -0.888 | -0.563 | -1.02 |